Trials / Conditions / Hypereosinophilic Syndrome (HES)
Hypereosinophilic Syndrome (HES)
4 registered clinical trials studyying Hypereosinophilic Syndrome (HES) — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Not Yet Recruiting | Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and NCT07444567 | AstraZeneca | Phase 3 |
| Not Yet Recruiting | Eosinophil Subpopulations in Eosinophilic-associated Diseases NCT06911775 | University of Florence | — |
| Completed | TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause NCT06172751 | AstraZeneca | — |
| No Longer Available | MAP to Provide Access to Nilotinib, for Patients With HES NCT04498871 | Novartis Pharmaceuticals | — |